Developing a new imaging device for targeted cancer therapy
AC-225 Imaging R01 Transfer
This study is working on a new imaging device to help doctors see how a special cancer treatment, using a substance called 225Ac, moves around in the body, which could lead to better therapies for patients with acute myeloid leukemia and other cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Calif-Lawrenc Berkeley Lab NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-11159270 on NIH RePORTER |
What this research studies
This research focuses on creating an advanced gamma imaging device that combines innovative reconstruction techniques to enhance the sensitivity of imaging 225Ac, a promising isotope used in targeted alpha therapy for cancer treatment. By enabling in vivo imaging of this isotope, the project aims to improve the understanding of how radiopharmaceuticals distribute within the body, particularly in patients with acute myeloid leukemia and other malignancies. The goal is to facilitate the development and FDA approval of new treatments by providing better insights into the pharmacokinetics of these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other cancers that may benefit from targeted alpha therapy.
Not a fit: Patients with cancers that do not respond to targeted alpha therapy or those who are not eligible for imaging studies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with fewer side effects for patients.
How similar studies have performed: Previous research has shown promising results with targeted alpha therapy in treating various malignancies, indicating potential success for this novel imaging approach.
Where this research is happening
Berkeley, United States
- University of Calif-Lawrenc Berkeley Lab — Berkeley, United States (Active)
Researchers
- Principal investigator: Caravaca, Javier — University of Calif-Lawrenc Berkeley Lab
- Study coordinator: Caravaca, Javier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.